Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve
N. Engl. j. med; 383 (22), 2020
BACKGROUND The effects of rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve remain uncertain. METHODS In this randomized trial, we compared rivaroxaban (20 mg once daily) with dose adjusted warfarin (target international normalized ratio, 2.0 to 3.0) in patients with atria...